In addition, CC1+ cell numbers were recovered in the peak EAE LQ-treated group as compared to the vehicle-treated EAE group (Fig. ​(Fig.8C8C i–iv). Therapeutic treatment with 25 mg/kg LQ significantly decreases EAE-induced motor deficit as measured by rotorod motor performance To assess the functional significance of LQ treatment during pre-EAE and peak EAE, EAE mice in a separate experiment were subjected

to a motor test frequently used to assess spinal cord injury – rotorod motor performance. Inhibitors,research,lifescience,medical EAE was induced in PLP_EGFP mice and animals were ultimately organized into the following treatment groups: vehicle, pre-EAE LQ, or peak EAE LQ. 25 mg/kg LQ was administered to one group of mice beginning on day 0 (pre-EAE). When clinical disease in vehicle-treated EAE mice reached ~2.5–3 at day 20, treatment with 25

mg/kg LQ was initiated (peak EAE). EAE scores of pre-EAE 25 mg/kg LQ-treated mice were significantly improved throughout Inhibitors,research,lifescience,medical the duration of disease. Contrastingly, the 25 mg/kg peak EAE LQ group showed significant improvement only after 7 days Inhibitors,research,lifescience,medical of continuous treatment, as compared to vehicle-treated EAE mice. Normal mice did not show any signs of disease and their clinical scores BI 6727 supplier remained 0 throughout the experiment (Fig. 9A). Figure 9 Prophylactic and therapeutic treatment with 25 mg/kg laquinimod (LQ) significantly decreases EAE-induced motor deficit, as measured by rotorod motor performance.

(A) In a separate experiment, Inhibitors,research,lifescience,medical PLP_EGFP C57BL/6 female mice were given 25 mg/kg LQ via oral … Vehicle-treated EAE mice demonstrated an abrupt and consistent decrease in the time (seconds) they were able to remain on the rotorod beginning at day 15 after disease induction, and this disability remained throughout the observation period. When the average EAE score reached ~2.5, vehicle-treated EAE animals that were switched to 25 mg/kg LQ treatment Inhibitors,research,lifescience,medical (at day 20) initially showed significant motor disability. However, within 5–7 days after initiation of treatment, motor disability was less severe. By day 30–40, the LQ-treated EAE group exhibited significant recovery in motor function (**P < 0.05, ANOVA, n = 10 animals/group; Fig. 9B). Discussion Our study demonstrates that LQ treatment is effective in ameliorating Endonuclease EAE clinical disease even after EAE-induced inflammation, axon damage, and demyelination have been initiated. We analyzed callosal white matter integrity in addition to spinal cord, as the CC in MS reflects demyelinating lesions, diffuse tissue damage, and abnormalities in neural connectivity, making it a potentially useful surrogate marker of clinically significant brain abnormalities (Boroojerdi et al. 1998; Warlop et al. 2008a,b; Ozturk et al. 2010).